Pfizer (PFE)

AbbVie still looks like a compelling buy at its all-time high.

According to a new report from Intel Market Research, the global Oral Contraceptive Drugs market was valued at USD 12.9 billion in 2024 and is projected to

Rep. Thomas Massie questions JD Vance's silence after the Trump CDC established a $1.24 Billion Pfizer COVID-19 vaccine contract.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical...

Far from "yield traps," these high-yield dividend stocks represent good value at current prices.

Pfizer has a 6.8% yield at a time when the market's yield is roughly 1%: Is there something wrong?

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...

Could it become as successful in this niche as it was in the coronavirus vaccine market?

Income seekers shouldn't give up on the stock yet.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

A strong yield and an impressive track record of dividend growth aren't enough. The underlying business needs to be enduring.

A Premarin shortage in India leaves menopausal patients facing limited treatment options as Pfizer halts cream distribution.

It is definitely a strong contender.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline...

Pfizer is a highly respected drug company facing normal industry headwinds.

Pfizer's dividend yield is 7% for a very good reason: investors are worried about the risk of a dividend cut.

All three can be bought on the dip.

These stocks offer a good mix of dividends, growth, and long-term stability.

The pharma giant's yield of around 7.1% is more than six times the S&P 500 average.

Cathie Wood's biotech ETF has largely moved on from the vaccine maker.

Drug pricing matters, but pipelines matter even more.